Growth Factors in Pituitary Tumors

Pituitary

Volumn 1, Issue 3-4, 1999, Pages 153-158

  Missale, Cristina ^a   Fiorentini, Chiara ^a   Finardi, Alessandra ^a   Spano, PierFranco ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Bromocriptine; Dopamine; Lactotrope cells; Nerve growth factor; Prolactinomas

Indexed keywords

DOPAMINE; GROWTH PROMOTOR; NERVE GROWTH FACTOR; PROLACTIN;

ADENOHYPOPHYSIS; ADENOMA; HUMAN; HYPOPHYSIS TUMOR; METABOLISM; REVIEW; SECRETION;

ADENOMA; DOPAMINE; GROWTH SUBSTANCES; HUMANS; NERVE GROWTH FACTOR; PITUITARY GLAND, ANTERIOR; PITUITARY NEOPLASMS; PROLACTIN;

EID: 0033123112     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1009996712678     Document Type: Article

References (66)

1. Kovacs K, Scheithauer BW, Horvath E, Lloyd RV. The World Health Organization classification of adenohypophysial neoplasms. A proposed five-tier scheme. Cancer 1996;78:502-510.
2. Davis JRE, Sheppard MC, Heath DA. Giant invasive prolactinoma: A case report and review of nine further cases. Q J Med 1990;74:227-238.
3. Cunnah D, Besser GM. Management of prolactinomas. Clin Endocrinol 1991;34:231-235.
4. Wass JA, Besser GM. The medical management of hormone-secreting tumors of the pituitary. Annu Rev Med 1983;34: 283-294.
5. De Camilli P, Macconi D, Spada A. Dopamine inhibits adenylate cyclase in human prolactin secreting adenomas. Nature 1979;278:252-254.
6. Ben-Jonathan N. Dopamine: A prolactin-inhibiting hormone. Endocrine Rev 1985;6:564-588.
7. Spark RF, Baker R, Bienfang DC, Bergland R. Bromocriptine reduces pituitary tumor size and hypersecretion. J Am Med Assoc 1982;247:311-316.
8. Liuzzi A, Dallabonzana D, Oppizzi G, Verde GG, Cozzi R, Chiodini P, Luccarelli G. Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med 1985;313:656-659.
9. Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, Joplin G, Robbins RJ, Tyson J, Thorner MO. Bromocriptine as a primary therapy for prolactin-secreting macroadenomas: Results of a prospective multicenter study. J Clin Endocrinol Metab 1985;60:698-705.
10. Pellegrini I, Rosolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedyank CP, Kordon C, Peillon F, Jaquet P, Enjalbert A. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 1989;69:500-509.
11. Missale C, Boroni F, Losa M, Giovanelli M, Zanellato A, Dal Toso R, Balsari A, Spano PF. Nerve growth factor suppresses the transforming phenotype of human prolactinomas. Proc Natl Acad Sci USA 1993;90:7961-7965.
12. Bossé R, Fumagalli F, Jaber M, Giros B, Gainetdinov RR, Wetsel WC, Missale C, Caron MG. Anterior pituitary hypoplasia and dwarfism in mice lacking the dopamine transporter. Neuron 1997;19:127-138.
13. 2 receptors causes hormonal dysfunction and pituitary hyperplasia. Neuron 1997;19:115-126.
14. 2 receptor-deficient mice. Neuron 1997;19:103-114.
15. Voss JW, Rosenfeld MG. Anterior pituitary development: short tales from dwarf mice. Cell 1992;70:527-530.
16. Ingraham HA, Chen R, Mangalam HJ, Elsholtz HP, Flynn SE, Lin CR, Simmons DM, Swanson L, Rosenfeld MG. A tissue-specific transcription factor containing a homeodomain specifies a pituitary phenotype. Cell 1988;55:519-529.
17. Mangalam HJ, Albert VR, Ingraham HA, Kapiloff M, Wilson L, Nelson C, Elsholtz H, Rosenfeld MG. A pituitary POU domain protein, Pit-1/GHF1, activates both growth hormone and prolactin promoters transcriptionally. Genes Dev 1989;3:946-958.
18. Lin SC, Lin CR, Gukovsky I, Lusis AJ, Sawchenko PE, Rosenfeld MG. Molecular basis of the little mouse phenotype and implications for cell-type specific growth. Nature 1993; 364:208-213.
19. Borgundvaag B, Kudlow JE, Muller SG, George SR. Dopamine receptor activation inhibits estrogen-stimulated transforming growth factor a gene expression and growth in anterior pituitary, but not in uterus. Endocrinology 1992; 130:3453-3458.
20. Sarkar DK, Gottschall PE, Meites J. Damage to hypothalamic dopaminergic neurons is associated with development of prolactin-secreting pituitary tumors. Science 1982;218: 684-686.
21. Amara SG, Kuhar MJ. Neutransmitter transporters: recent progress. Annu Rev Neurosci 1993;16:73-93.
22. Giros B, Caron MG. Molecular characterization of the dopamine transporter. Trends Pharmacol Sci 1993;14:43-49.
23. Giros B, Jaber M, Jones SR, Wightmann RM, Caron MG. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996; 379:606-612.
24. Fan X, Childs GV. Epidermal growth factor and transforming growth factor-α messenger ribonucleic acids and their receptors in the rat anterior pituitary: Localization and regulation. Endocrinology 1995;136:2284-2293.
25. Chabot JG, Walker P, Pelletier G. Distribution of epidermal growth factor binding sites in the adult anterior pituitary gland. Peptides 1986;7:45-50.
26. Childs GV, Rougeau D, Unabia G. Corticotropin-releasing hormone and epidermal growth factor: mitogens for anterior pituitary corticotropes. Endocrinology 1995;136:1595-1062.
27. Felix R, Meza U, Cota G. Induction of classical lactotropes by epidermal growth factor in rat pituitary cell cultures. Endocrinology 1995;136:939-946.
28. 3 cell line. Endocrinology 1990;127:13-20.
29. Altschuler LR, Parisi MN, Cageao LF, Chiocco SR, Fernandez-Pol JA, Zaninovich AA. Epidermal growth factor stimulates thyrotropin secretion in the rat. Neuroendocrinology 1993;57:23-27.
30. Childs GV, Patterson J, Unabia G, Rougeau D, Wu P. Epidermal growth factor enhances ACTH secretion and expression of POMC mRNA by corticotropes in mixed and enriched cultures. Mol Cell Neurosci 1991;2:235-243.
31. Miyake A, Tasaka K, Otsuka S, Kohmura H, Wakimoto H, Aono T. Epidermal growth factor stimulates secretion of rat pituitary luteinizing hormone-releasing hormone in vitro. Acta Endocrinol 1985;108:175-178.
32. Polk DH, Ervin MG, Padbury JF, Lam RW, Reviczky AL, Fisher DA. Epidermal growth factor acts as a corticotropin-releasing factor in chronically catherized fetal lambs. J Clin Invest 1987;79:984-988.
33. Finley EL, King JS, Ramsdell JS. Human pituitary somatotrophs express transforming growth factor α and its receptors. J Endocrinol 1994;141:547-554.
34. Kobrin MS, Asa SL, Samsoondar J, Kudlow JE. α-Transforming growth factor in the bovine anterior pituitary gland: Secretion by dispersed cells and immunohistochemical localization. Endocrinology 1987;121:1412-1416.
35. Samsoondar J, Kobrin MS, Kudlow JE. Transforming growth factor α secreted by untransformed bovine anterior pituitary cells in culture. Purification from conditioned medium. J Biol Chem 1986;261:14408-14413.
36. Driman DK, Kobrin MS; Kudlow JE, Asa SL. Transforming growth factor-alpha in normal and neoplastic human endocrine tissues. Hum Pathol 1992;23:1360-1365.
37. Ren P, Scheithauer BW, Halper J. Immunohistochemical localization of TGFα, EGF, IGF-1 and TGBFβ in the normal human pituitary gland. Endocr Pathol 1994;5:40-48.
38. McAndrew J, Paterson AJ, Asa SL, McCarthy KJ, Kudlow JE. Targeting of transforming growth factor-α expression to pituitary lactotrophs in transgenic mice results in selective lactotroph proliferation and adenomas. Endocrinology 1995; 136:4479-4488.
39. 1-like immunoreactivity in the pituitary gland of the rat: effect of estrogen. Endocrinology 1993;133:1444-1449.
40. Qian X, Jin L, Grande JP, Lloyd RV. Transforming growth factor-β and p27 expression in pituitary cells. Endocrinology 1996;137:3051-3060.
41. Sarkar DK, Kim KH, Minami S. Transforming growth factor-β1 messenger RNA and protein expression in the pituitary gland: its action on prolactin secretion and lactotropic growth. Mol Endocrinol 1992;6:1825-1833.
42. Albaladejo V, Fei ZL, Nicolas B, Joly-Pharaboz MO, Avallet O, Vigier M, Andre J. Possible involvement of transforming growth factor β in the inhibition of rat pituitary tumor growth by estradiol. J Steroid Biochem Mol Biol 1992;41: 125-134.
43. 3 cells. Mol Endocrinol 1991;5:1716-1722.
44. Pastorcic M, De A, Boyadjieva N, Vale W, Sarkar DK. Reduction in the expression and action of transforming growth factor β1 on lactotropes during estrogen-induced tumorigenesis in the anterior pituitary. Cancer Res 1995;55:4892-4898.
45. Levi-Montalcini R. The nerve growth factor 35 years later. Science 1987;237:1154-1162.
46. Levi-Montalcini R, Skaper SD, Dal Toso R, Petrelli L, Leon A. Nerve growth factor: From neurotrophin to neurokine. Trends Neurosci 1996;19:514-520.
47. Kaplan DR, Hempstead BL, Martin-Zanca D, Chao MV, Parada LF. The trk proto-oncogene product: A signal transducing receptor for nerve growth factor. Science 1991;252: 554-558.
48. Klein R, Jing S, Nanduri V, O'Rourke E, Barbacid M. The trk proto-oncogene encodes a receptor for nerve growth factor. Cell 1991;65:189-197.
49. Radeke MJ, Miska PP, Hsu C, Herzenberg LA, Shooter EM. Gene transfer and molecular cloning of the rat nerve growth factor receptor. Nature 1987;325:593-597.
50. Segal RA, Greenberg ME. Intracellular signalling pathways activated by neurotrophic factors. Annu Rev Neurosci 1996; 19:463-469.
51. Bothwell M. Functional interactions of neurotrophins and neurotrophin receptors. Annu Rev Neurosci 1995;18:223-253.
52. NTR. A receptor after all. Science 1996;272: 506-507.
53. NTR decide? Neuron 1997;18:187-190.
54. Carter BD, Kaltschmidt C, Kaltschmidt B, Offenhauser N, Bohm-Matthaei R, Bauerle PA, Barde YA. Selective activation of NFκB by nerve growth factor through the neurotrophin receptor p75. Science 1996;272:542-545.
55. Dobrowsky RT, Werher MM, Castellino AM, Chao MV, Hannun YA. Activation of the sphingomyelin cycle through the low affinity neurotrophin receptor. Science 1994;265:1596-1599.
56. Missale C, Boroni F, Sigala S, Buriani A, Fabris M, Leon A, Dal Toso R, Spano PF. Nerve growth factor in the anterior pituitary: localization in mammotroph cells and co-secretion with prolactin by a dopamine-regulated mechanism. Proc Natl Acad Sci USA 1996; 93:424-4245.
57. Patterson JC, Childs GW. Nerve growth factor and its receptor in the interior pituitary. Endocrinology 1994;135: 1689-1696.
58. Burnham P, Conner JM, Varon S. Co-localization of NGF and TSH-like immunoreactivity in cultures of adult rat anterior pituitary cells. J Neurosci Res 1995;41:73-78.
59. Missale C, Boroni F, Frassine M, Caruso A, Spano PF. Nerve growth factor promotes the differentiation of pituitary mammotroph cells in vitro. Endocrinology 1995;136:1205-1213.
60. Porter TE, Wiles CD, Frawley LS. Stimulation of lactorope differentiation in vitro by fibroblast growth factor. Endocrinology 1994;134:164-168.
61. Borrelli E, Sawchenko PE, Evans RM. Pituitary hyperplasia induced by ectopic expression of nerve growth factor. Proc Natl Acad Sci USA 1992;89:2764-2768.
62. 1 rat pituitary tumors and appears necessary for tumor formation. Endocrinology 1994;135:416-422.
63. 4 pituitary tumor cell proliferation. Endocrinology 1991;128:1981-1990.
64. Ezzat S, Walpola IA, Ramyar L, Smyth HS, Asa SL. Membrane-anchored expression of transforming growth factor-alpha in human pituitary adenoma cells. J Clin Endocrinol Metab 1995;80:534-539.
65. Missale C, Losa M, Sigala S, Balsari A, Giovanelli M, Spano PF. Nerve growth factor controls proliferation and progression of human prolactinoma cell lines through an autocrine mechanism. Mol Endocrinol 1996;10:272-285.
66. Missale C, Losa M, Boroni F, Giovanelli M, Balsari A, Spano PF. Nerve growth factor and bromocriptine: a sequential therapy for human bromocriptine-resistant prolactinomas. Br J Cancer 1995;72:1397-1399.